Researcher

Aarts - Essers, M.J.B.

Assistant Professor, UMS

View graph of relations
  1. 2019
  2. Published
  3. Published
    Jochems, A., van der Kooij, M. K., Fiocco, M., Schouwenburg, M. G., Aarts, M. J., van Akkooi, A. C., ... Kapiteijn, E. (2019). Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. Cancers, 11(7), [1007]. https://doi.org/10.3390/cancers11071007
  4. Published
  5. 2018
  6. Published
  7. Published
    Groot, H. J., Gietema, J. A., Aleman, B. M. P., Incrocci, L., de Wit, R., Witjes, J. A., ... Schaapveld, M. (2018). Risk of diabetes after para-aortic radiation for testicular cancer. British Journal of Cancer, 119(7), 901-907. https://doi.org/10.1038/s41416-018-0248-x
  8. Published
    Groot, H. J., Lubberts, S., de Wit, R., Witjes, J. A., Kerst, J. M., de Jong, I. J., ... Schaapveld, M. (2018). Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. Journal of Clinical Oncology, 36(24), 2504-2513. https://doi.org/10.1200/JCO.2017.77.4174
  9. Published
    Schouwenburg, M. G., Jochems, A., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., ... van der Hoeven, J. J. M. (2018). Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 28(4), 326-332. https://doi.org/10.1097/CMR.0000000000000453
  10. Published
  11. Published
    Franken, M. G., Leeneman, B., Jochems, A., Schouwenburg, M. G., Aarts, M. J. B., van Akkooi, A. C. J., ... Uyl-de Groot, C. A. (2018). Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29(6), 579-588. https://doi.org/10.1097/CAD.0000000000000628
  12. Published
    Jochems, A., Leeneman, B., Franken, M. G., Schouwenburg, M. G., Aarts, M. J. B., van Akkooi, A. C. J., ... van der Hoeven, K. J. M. (2018). Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29(6), 572-578. https://doi.org/10.1097/CAD.0000000000000629
  13. Published
    van Zeijl, M., van den Eertwegh, A. J. M., Wouters, M. W. J. M., Jochems, A., Schouwenburg, M. G., Haanen, J. B. A. G., ... van der Hoeven, K. J. (2018). Recente behandelresultaten van uitgezaaid melanoom. Nederlands Tijdschrift voor Geneeskunde, 162, 1-10. [D2420].
  14. 2017
  15. Published
  16. Published
  17. Published
  18. Published
  19. Published
  20. Published
  21. Published
  22. Published
  23. Published
    Jochems, A., Schouwenburg, M. G., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., ... van der Hoeven, J. J. M. (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. https://doi.org/10.1016/j.ejca.2016.11.021
  24. Published
  25. Published
  26. 2016
  27. Published
  28. Published
    Badrising, S. K., van der Noort, V., van den Eertwegh, A. J. M., Hamberg, P., van Oort, I. M., van den Berg, H. P., ... Bergman, A. M. (2016). Prognostic Parameters for Response to Enzalutamide After Docetaxel and Abiraterone Treatment in Metastatic Castration-Resistant Prostate Cancer Patients: a Possible Time Relation. Prostate, 76(1), 32-40. https://doi.org/10.1002/pros.23094
  29. Published
  30. Published
    Badrising, S. K., van der Noort, V., Hamberg, P., Coenen, J. L. L. M., Aarts, M. J., van Oort, I. M., ... Bergman, A. M. (2016). Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology, 91(5), 267-273. https://doi.org/10.1159/000448219
  31. 2015
  32. Published
  33. 2013
  34. Published
  35. Published
  36. Published